Developing new technologies to create inhibitors for carbohydrate-binding proteins
Official title: Technology for Directed Evolution of Glycoaptamers
Funded at Brandeis University · NIH-11099100 · Data updated 2026-11-12
This study is working on new tools that can help find ways to block certain proteins that are important in diseases like cancer, diabetes, and heart issues, using special RNA molecules to better target these proteins and improve treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brandeis University NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $160,926 |
| NIH project number | 3R01GM151492-02S1 |
| Project ID | NIH-11099100 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with conditions such as atherosclerosis, diabetes, autoimmune diseases, or cancers where carbohydrate-binding proteins play a significant role.
✕Less likely to help
Patients with conditions unrelated to carbohydrate-binding protein interactions may not benefit from this research.
What this research studies
This research focuses on creating innovative technologies to quickly discover inhibitors that target carbohydrate-binding proteins (CBPs), which play a crucial role in various biological processes such as immune response, cancer progression, and chronic diseases like diabetes and atherosclerosis. The approach involves developing specialized RNA-based molecules that can selectively bind to these proteins, disrupting their interactions with carbohydrates. By enhancing the binding affinity and specificity of these inhibitors, the research aims to provide effective tools for studying and potentially treating diseases linked to CBP functions.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients suffering from diseases related to carbohydrate-binding protein interactions.
How similar studies have gone: Other research has shown promise in targeting carbohydrate-binding proteins, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Brandeis University
Waltham, United States Active
Researchers
- Principal investigator: Krauss, Isaac Jonathan — Brandeis University
- Study coordinator: Krauss, Isaac Jonathan
Related research
Other NIH-funded projects on the same topics.
-
Unwinding SNAP aid and its effect on healthcare and disparities
A large study will look at how cutting back food assistance like SNAP changes healthcare use and outcomes, especially for people with differing levels of food insecurity.
-
Roles of Recycling Endosomes in Neuronal EV Cargo Traffic
A scientist at Brandeis University is studying how brain cells control the tiny vesicles they release, which may affect memory loss in Alzheimer’s disease.
-
Sulfur-stabilized HIV glycoconjugates to help create powerful bnAbs
Researchers are testing sugar-coated HIV vaccine components in animals to see if they can better trigger broadly-protective antibodies.
-
Cycling Molecular Assemblies to Target Golgi Traffic in Cancer Cells
A novel, first-of-its-kind approach uses tiny, self-organizing molecular structures to selectively disrupt Golgi trafficking in cancer cells, aiming to influence how cancer cells grow and respond to signals.
-
How low oxygen and genetic tweaks may repair mitochondrial problems linked to Alzheimer’s and other disorders
A Johns Hopkins-style? (Note: institution specified later) patient-facing overview: researchers will study tiny cell power stations in mitochondria to see if low-oxygen conditions and specific genetic changes can fix problems associated with Alzheimer's disease and related dementias.
-
Synthesis of thioaminoketal antimicrobial peptides and how they work
Researchers are developing new antimicrobial peptides called sactipeptides and figuring out precisely how they kill bacteria.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.